Two Swiss mid-cap pharmaceutical companies are drawing renewed attention from value investors after a confluence of discounted valuations, projected earnings growth and analyst upgrades. Basilea and Siegfried, both listed in Switzerland, are trading at forward price-to-earnings ratios of 16.5 times estimated 2027 results, below their respective long-term averages and below those of larger peers Roche and Novartis.
Basilea, a biotech focused on antibiotics and antifungals, has seen its shares rise more than 21% in recent weeks after reporting strong half-year results that eased concerns over the impending loss of exclusivity for its antifungal drug Cresemba. The U.S. Cresemba patent expires in the fourth quarter of 2027, with European protection ending in the second half of 2028. Analysts now expect 2027 revenue growth of approximately 14% and earnings-per-share growth of 21%, up from a 35% downgrade a year ago. The company’s pipeline includes Fosmanogepix and Ceftibuten-Ledaborbactam, with U.S. Phase 3 trials for invasive candidiasis and aspergillosis proceeding as planned. CEO David Veitch highlighted a replicable pipeline model that leverages partnerships and non-dilutive funding, aiming to generate peak product revenues of CHF 0.5 to 1 billion per drug without direct competition from major pharmaceutical groups.
Siegfried, a contract development and manufacturing organization specializing in chemical active ingredients and dosage forms, has faced pressure alongside peers such as Lonza and Bachem following the post-pandemic destocking cycle in the pharmaceutical industry. The company’s net leverage stands at 1.5 times EBITDA, and free cash flow yield turned positive at 0.3% last year after a decline in 2025. Analysts project 2027 revenue growth of 17% and EPS growth of 26%, with Deutsche Bank noting that the company remains on track to meet 2026 targets and anticipating improved organic growth in 2027. Two-thirds of analysts covering Siegfried rate the stock a buy, with an average price target of CHF 99, implying upside of more than 38% from the current CHF 71.80.
Both companies benefit from upward earnings revisions. Basilea’s EPS outlook for 2027 has improved from a 35% cut a year ago to a 20% decline, while Siegfried’s forecast shifted from a 3.3% decrease to a 3.2% increase. In contrast, Roche and Novartis are expected to grow EPS by 14% and 24% respectively, but trade at higher forward multiples of 16.7 times, above their long-term averages.
Investors should note risks. Basilea’s valuation may still reflect a value trap if pipeline successors fail to offset the Cresemba revenue gap post-2028, with some estimates projecting 2028 EPS as low as CHF 1.94 under a downside scenario. The company carries no debt and generates a free cash flow yield of 7.7%, providing flexibility for pipeline expansion or shareholder returns, though dividends are not currently prioritized. Siegfried’s low dividend yield may disappoint income-focused investors if the stock remains range-bound.
